Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869242 | 0.89 | TRPV1 (0.53) | TRPV1MAPK3 | |
| SCHEMBL1857549 | 0.88 | TRPV1 (0.41) | TRPV1KMT2AMEN1MRGPRX4SORT1 | |
| SCHEMBL1860856 | 0.86 | TRPV1 (0.41) | TRPV1MRGPRX4LRRK2 | |
| SCHEMBL3961094 | 0.85 | TRPV1 (0.44) | TRPV1MAPK3MRGPRX4LRRK2 | |
| SCHEMBL1861308 | 0.84 | SYK (0.34) | TRPV1KMT2AMEN1 | |
| SCHEMBL1862804 | 0.78 | TRPV1 (0.53) | TRPV1MAPK3KMT2AMEN1 | |
| SCHEMBL1856817 | 0.77 | TRPV1 (0.69) | TRPV1MAPK3 | |
| SCHEMBL1865066 | 0.77 | TRPV1 (0.49) | TRPV1MAPK3SORT1 | |
| SCHEMBL1867816 | 0.76 | TRPV1 (0.49) | TRPV1MAPK3MRGPRX4 | |
| SCHEMBL1867111 | 0.75 | MRGPRX4 (0.39) | TRPV1MRGPRX4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885MAPK3 2884/4885KMT2A 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.